At the cutting edge of stroke research right here in France #ESOC2022!
Here are nine things I learnt from nine trials today!
#NeuroTwitter
Here are nine things I learnt from nine trials today!
#NeuroTwitter
(1/9) AcT: tenecteplase is not inferior to alteplase in acute ischaemic stroke.
(2/9) NOR-TEST 2A: tenecteplase at 0.4mg/kg is not non-inferior to alteplase (worse safety and functional outcome), but perhaps this dose is too high.
(3/9) TASTE-A: tenecteplase results in a superior rate of early reperfusion compared with alteplase when administered in a Mobile Stroke Unit.
(4/9) ParaNASPP: structured learning program re: prehospital NIHSS led to better functional outcome in the intervention group.
(5/9) SPRINT: structured SMS message, education video, workbook, and telephone follow-up improved lifestyle and medication adherence.
(6/9) ATTICUS: apixaban is not superior to ASA with switch to apixaban in case of AF in prevention of new ischaemic lesions at 12 months for embolic stroke of undetermined source.
(7/9) SETPOINT2: early versus late tracheostomy in ventilated stroke patients did not lead to better functional outcome at 6m.
(8/9) AMETIS: procedural sedation and GA for endovascular stroke management resulted in similar rates of functional independence and major periprocedural complications.
(9/9) ATTENTION: endovascular thrombectomy was superior to best medical management in acute basilar artery occlusion within <12hrs.
Loading suggestions...